Physician profile
Amy Werchinski
NPI 1265466171
$2,978.72
in general payments reported to CMS, 2019-2025
16 companies · $475 in 2025
The $475 reported for 2025 was more than what 79% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $583 · 2023: $1,006 · 2024: $651 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.07 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $463.71 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $394.29 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $308.36 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $291.92 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $275.57 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Amgen INC. | $266.05 | 2022-2024 | Otezla |
| Pfizer INC. | $200.94 | 2021-2025 | |
| Dermavant Sciences, INC. | $162.99 | 2023-2024 | Vtama |
| Genzyme Corporation | $125.93 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $107.46 | 2023-2024 | Sotyktu |
| Incyte Corporation | $107.27 | 2022-2025 | Opzelura |
| Ucb, INC. | $83.23 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $58.29 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.23 | 2023-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $40.08 | 2024 | Zoryve |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $36.40 | 2024-2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Werchinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.